Introduction to the Immunocompromised Host Society consensus conference on epidemiology, prevention, diagnosis, and management of infections in solid-organ transplant patients.
Infectious complications are still a significant cause of morbidity and death in solid-organ transplant patients, with significant infection being found in up to two-thirds of these individuals. The risk of infection in the organ transplant patient, particularly of opportunistic infection, is largely determined by 3 factors: the net state of immunosuppression, the epidemiologic exposures the patient encounters, and the consequences of the invasive procedures to which the patient is subjected. The most important principles of patient treatment are prevention, early diagnosis, and specific therapy. This issue is designed as a position paper by a group of experts on epidemiology, prevention, diagnosis, and management of infections in solid-organ transplant patients. We feel that our efforts may serve as an important first step in the development of guidelines in this area.
Rubin
R H
RH
Center for Experimental Pharmacology and Therapeutics, Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02142-1308, USA. rhrubin@mit.edu
Schaffner
A
A
Speich
R
R
D000890:Anti-Infective Agents / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology*; D009894:Opportunistic Infections / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control / Q000628:therapy; D016377:Organ Transplantation; D011183:Postoperative Complications / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control; D014181:Transplantation Immunology
D000890:Anti-Infective Agents